A Phase IV, Multi-Center, Open-Label Study to Determine the Safety, Tolerability and Clinical Outcomes Following Oral Administration of EGATEN™ (Triclabendazole) in Patients (6 Years of Age or Older) with Fascioliasis

Study code: 24MA
Start date: Nov-19 End date: Ongoing
CT registration number: TBC